Back to School: How biopharma can reboot drug development. Access exclusive analysis here
INDICATION: Non-small cell lung cancer (NSCLC)
Studies in mice suggest dual inhibition of IRS1
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury